Correlative biomarker analysis of sequential tumor biopsies in a ph I mode of action (MoA) study in neoadjuvant head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with RG7160 (GA201), a novel dual-acting, monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), with cetuximab (C) as reference.
Christoph Mancao
Employment or Leadership Position - Roche
Stock Ownership - Roche
Lilla Di Scala
Employment or Leadership Position - Roche
Stock Ownership - Roche
Paul Delmar
Employment or Leadership Position - Roche
Stéphane Temam
Honoraria - Roche
Jean-Charles Soria
Consultant or Advisory Role - Roche
Honoraria - Roche
James F. Spicer
Research Funding - Guys Hospital
Mark McGurk
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Jerome Sarini
No relevant relationships to disclose
Niels Halama
Research Funding - Roche
Stefan Evers
Employment or Leadership Position - Roche
Stock Ownership - Roche
Alexandre Passioukov
Employment or Leadership Position - Roche